http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Li Ko-Jen (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Design of High Efficiency Multi-Phase QR ZCS Switched-Capacitor Bidirectional Power Converters
Yi-Pin Ko,Yuang-Shung Lee,Li-Jen Liu 전력전자학회 2011 ICPE(ISPE)논문집 Vol.2011 No.5
The multi-phase implementation in the quasi resonant (QR) zero current switching (ZCS) switched capacitor (SC) bidirectional DC-DC converter structure has been proposed to reduce current ripple, switching loss and significantly increase the converter efficiency and power density. This approach provides a more precise output voltage to obtain voltage conversion ratios from the doublemode versus half-mode to n-mode versus 1/n mode. This is accomplished by adding a different number of switched-capacitors and power MOSFET switches with a small series connected resonant inductor for forward and reverse schemes. The size and cost can be reduced when the proposed converter has designed with the coupled inductors. The simulation and experimental results have been used to demonstrate the performance of the two-phase with and without coupled inductor interleaved QR ZCS SC converters for bidirectional power flow control application, and an extending structure for N-phase is mentioned.
-
Lan Ting-Yuan,Lin Yen-Chun,Tseng Tai-Chung,Yang Hung-Chih,Kao Jui-Hung,Cheng Chiao-Feng,Lee Tai-Ju,Huang Shang-Chin,Lu Cheng-Hsun,Li Ko-Jen,Hsieh Song-Chou 거트앤리버 소화기연관학회협의회 2023 Gut and Liver Vol.17 No.2
Background/Aims: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort. Methods: From March 2006 to December 2019, 900 patients with negative HBsAg receiving at least one cycle of rituximab for autoimmune diseases in a tertiary medical center in Taiwan were retrospectively reviewed. Clinical outcome and factors associated with HBVr were analyzed. Results: After a median follow-up period of 3.3 years, 21 patients developed HBVr, among whom 17 patients were positive for hepatitis B core antibody (anti-HBc) and four were negative. Thirteen patients had clinical hepatitis flare, while eight patients had HBsAg seroreversion without hepatitis. Old age, anti-HBc positivity, undetectable serum hepatitis B surface antibody level at rituximab initiation and a higher average rituximab dose were associated with a higher HBVr rate. There was no significant difference in the HBVr risk between rheumatoid arthritis and other autoimmune diseases. Among anti-HBc-negative patients, subjects without HBV vaccination at birth had an increased risk of HBVr (4/368, 1.1%) compared with those who received vaccination (0/126, 0%). Conclusions: In HBV endemic areas where occult HBV is prevalent, anti-HBc-negative patients, may still be at risk for HBVr after rituximab exposure. HBVr may still be considered in HBsAgnegative patients developing abnormal liver function after rituximab exposure, even in patients with negative anti-HBc.
KCI연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
